We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

The Clinical Significance of Acid Rebound in Functional Dyspepsia (CLARIFY)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01373970
Recruitment Status : Terminated
First Posted : June 15, 2011
Last Update Posted : December 6, 2013
Information provided by (Responsible Party):
Anders Bergh Loedrup, Zealand University Hospital

Brief Summary:

Proton pump inhibitors (PPI) have been shown to cause acid reflux related symptoms at withdrawal in healthy volunteers, a phenomenon known as Rebound Acid Hyper Secretion. Whether this also applies for patients with dyspeptic symptoms but without true reflux disease (functional dyspepsia) treated with PPI is unknown. If this is the case, it could lead to an unfortunate long term use of PPI, since the acid rebound renders withdrawal too difficult.

This is a single centre, randomized, double-blinded, placebo-controlled cross over study. Study period is 12 weeks per study subject. Study subjects are referred to the study from General Practitioner (GP) and the gastroenterology department or endoscopy clinic of the investigational centre.

The study population consists of patients who seek their GP because of dyspepsia without alert signs, and whom the GP may consider starting on PPI. Out patients referred to the gastroenterology department or endoscopy clinic of the investigational centre because of dyspepsia without specific exclusion criteria are also invited to participate.

Baseline interview, upper endoscopy and pH monitoring are performed one week before inclusion to exclude patients with GERD. Helicobacter Pylori (Hp.) status is assessed by Helicobacter Urease Test (HUT). Hp. positive subjects without ulcus are not excluded.

Patients with a positive pH monitoring will not be included in the analysis regarding the primary endpoint (Development of GERD) but will be included in the analysis regarding one of the secondary endpoints (Effect of PPI on Functional Dyspepsia).

Study subjects are randomized to either pantoprazol followed by cross over to placebo or to placebo. Escape medication in the form of Gaviscon can be used on demand.

Internet based questionnaires are answered weekly. Questionnaires consist of the Gastrointestinal Symptom rating Scale (GSRS) in combination with items assessing postprandial fullness and items assessing the Montreal Criteria for Gastro Esophageal Reflux Disease (GERD).

Compliance to protocol is assessed at hospital visits every fourth week. At the end of study endoscopy and pH monitoring are repeated.

Condition or disease Intervention/treatment Phase
Functional Dyspepsia Drug: Placebo Drug: Pantoprazole + Placebo Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 184 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: The Clinical Significance of Acid Rebound: Symptoms of Reflux After PPI Treatment in Patients With Functional Dyspepsia
Study Start Date : May 2011
Actual Primary Completion Date : May 2013
Actual Study Completion Date : September 2013

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Indigestion

Arm Intervention/treatment
Placebo Comparator: Placebo Drug: Placebo
Placebo, one tablet daily for 12 weeks

Active Comparator: PPI + Placebo
PPI followed by cross over to placebo
Drug: Pantoprazole + Placebo
Pantoprazole 40 mg, one tablet daily in eight weeks followed by a blinded cross over to placebo, one tablet daily for four weeks

Primary Outcome Measures :
  1. Development of GERD [ Time Frame: week 9 - 12 ]
    Comparison of number of study subjects that develop GERD according to the Montreal definition including endoscopic findings and pH monitoring in weeks 9-12 in the PPI group versus the placebo group.

Secondary Outcome Measures :
  1. Use of escape medication [ Time Frame: Week 9 - 12 ]
    Difference in use of escape medication in weeks 9 - 12 between PPI- and placebo group

  2. Endoscopic findings [ Time Frame: 0 - 2 weeks before inclusion ]
    Number of study subjects who have esophagitis, peptic stricture or Barrett's esophagus at inclusion without having symptoms of reflux.

  3. pH monitoring [ Time Frame: 0 - 2 weeks before inclusion ]
    Number of study subject who have an abnormal pH monitoring at inclusion with-out symptoms of reflux

  4. Irritable Bowel Syndrome (IBS) [ Time Frame: 0 - 2 weeks before inclusion ]
    Number of study subjects with ROME III score indicating IBS at inclusion

  5. Irritable Bowel Syndrome (IBS) and treatment [ Time Frame: Week 0 - 12 ]
    Difference in symptom scores between study subjects with and without IBS in the PPI- and placebo group in weeks 0 - 12

  6. Effect of PPI on Functional Dyspepsia [ Time Frame: Week 8 ]
    Number of study subjects in the PPI group versus the placebo group that answer "no discomfort at all" or "slight discomfort" to dyspepsia related questions ("ache/pain in the upper part of the abdomen" and "hunger pains/hollow feeling in the stomach") in week 8.

  7. Helicobacter Pylori [ Time Frame: Week 9 - 12 ]
    Difference in symptom score for subject with and without H. Pylori between PPI- and placebo group in weeks 9 - 12.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Symptoms indicating dyspepsia, including:

    • Epigastric pain or epigastric discomfort
    • Bothersome postprandial fullness
    • Early satiation
    • Epigastric burning
  • Access to internet

Exclusion Criteria:

  • Daily use of PPI or H2-receptor antagonists in more than 28 days within the last 120 days OR more than two days within the last 28 days OR more than five non-consecutive days within the last 28 days.
  • Mild heartburn or regurgitation more than once per week
  • Moderate or severe heartburn or regurgitation at least once per week
  • Complications to GERD (esophagitis, stricture or Barrett's esophagus) prior to enrolment or at screening
  • Abnormal findings at upper endoscopy necessitating treatment
  • Abnormal pH-monitoring prior to enrolment or at screening (pH <4 in ≥5.5 % of the time on "worst day" of 48-h monitoring)

    • Excludes data from analysis regarding primary endpoint (see summary)
  • Previous surgery on esophagus, stomach or duodenum
  • Regular use of NSAIDs through the last six months
  • Potential language problems in understanding information and registering symptoms
  • Pregnancy or breast feeding
  • Other diseases which can interfere with the symptom registration (severe congestive heart disease, malignant disease, schizophrenia ect.)
  • Abuse of alcohol/narcotics
  • Allergy/intolerance to gelatine or lactose used in placebo
  • Patients with pacemaker, Implantable Cardioverter Defibrillator or Implantable Neurostimulator

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01373970

Layout table for location information
Koege Hospital
Koege, Denmark, 4600
Sponsors and Collaborators
Zealand University Hospital
Layout table for investigator information
Principal Investigator: Anders B. Lødrup, MD Zealand University Hospital
Layout table for additonal information
Responsible Party: Anders Bergh Loedrup, Doctor, Zealand University Hospital
ClinicalTrials.gov Identifier: NCT01373970    
Other Study ID Numbers: SJ-217
First Posted: June 15, 2011    Key Record Dates
Last Update Posted: December 6, 2013
Last Verified: December 2013
Keywords provided by Anders Bergh Loedrup, Zealand University Hospital:
Functional Dyspepsia
Protonpump inhibitor
Rebound Acid HyperSecretion
Additional relevant MeSH terms:
Layout table for MeSH terms
Signs and Symptoms, Digestive
Anti-Ulcer Agents
Gastrointestinal Agents
Proton Pump Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action